# OnCo record paper-kristine-lancet-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-kristine-lancet-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-kristine-lancet-oncol-2018" ;
  schema:name "Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial"@en ;
  schema:description "Published report from the KRISTINE trial registered as NCT02131064, in The Lancet Oncology (2018), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-kristine-lancet-oncol-2018/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(17)30716-7>, <https://pubmed.ncbi.nlm.nih.gov/29175149/>, <https://europepmc.org/article/MED/29175149>, <https://clinicaltrials.gov/study/NCT02131064> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(17)30716-7> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Hurvitz SA, Martin M, Symmans WF, et al." ;
  onco:trials <https://onco.cc/trials/kristine/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .